Citation Report
List of articles citing

Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review

DOI: 10.1159/000481438
Urologia Internationalis, 2018, 100, 251-262.

#	Paper	IF	Citations
126	Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. *Urologia Internationalis*, **2018**, 101, 38-46	1.9	23
125	Salvage CyberKnife-Based Reirradiation of Patients With Recurrent Prostate Cancer: The Single-Center Experience. **2018**, 17, 1533033818785496		13
124	Early Dutasteride Monotherapy in Patients With Elevated Serum Prostate-Specific Antigen Levels Following Robot-Assisted Radical Prostatectomy. **2019**, 9, 691		2
123	Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy. **2019**, 51, 2169-2180		5
122	Surgeon volume and body mass index influence positive surgical margin risk after robot-assisted radical prostatectomy: Results in 732 cases. **2019**, 17, 234-242		3
121	Tumor infiltrating M2 macrophages could predict biochemical recurrence of localized prostate cancer after radical prostatectomy. **2019**, 384, 111588		8
120	Direct Intercellular Communications and Cancer: A Snapshot of the Biological Roles of Connexins in Prostate Cancer. **2019**, 11,		15
119	High surgeon volume and positive surgical margins can predict the risk of biochemical recurrence after robot-assisted radical prostatectomy. *Therapeutic Advances in Urology*, **2019**, 11, 1756287219878283	3.2	3
118	Salvage treatment for radio-recurrent prostate cancer: a review of literature with focus on recent advancements in image-guided focal salvage therapies. **2019**, 51, 1101-1106		4
117	Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer. **2019**, 13, 420-426		7
116	The influence of BRCA2 mutation on localized prostate cancer. *Nature Reviews Urology*, **2019**, 16, 281-290	5.5	36
115	Percutaneous MR-guided prostate cancer cryoablation technical updates and literature review. **2019**, 1, 20180043		3
114	Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. *Nature Reviews Urology*, **2019**, 16, 7-22	5.5	22
113	Robot-assisted Placement of Pelvic Tissue Expander for Radiation After Prostatectomy and Cystectomy for Treatment of Prostate Cancer Biochemical Recurrence. **2019**, 124, 292-296		1
112	Risk factors of positive surgical margins after robot-assisted radical prostatectomy in high-volume center: results in 732 cases. **2020**, 14, 167-175		12
111	An F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with F-JK-PSMA-7 During the First Year of Application. **2020**, 61, 202-209		12
110	BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update. **2020**, 41, 9-17		3

109	Linear extent of positive surgical margin impacts biochemical recurrence after robot-assisted radical prostatectomy in a high-volume center. **2020**, 14, 663-675	6
108	Histotripsy: The Next Generation of High-Intensity Focused Ultrasound for Focal Prostate Cancer Therapy. **2020**, 39, 1057-1067	6
107	Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer. **2020**, 147, 1199-1205	3
106	Oncological safety and functional outcomes of testosterone replacement therapy in symptomatic adult-onset hypogonadal prostate cancer patients following robot-assisted radical prostatectomy. **2021**, 39, 3223-3229	4
105	A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence. **2020**, 20, 953	1
104	Detection Rate of Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy. **2020**, 8,	4
103	Association Between Contrast-Enhanced Ultrasound Indicators and Prostate Cancer Biochemical Recurrence After Treatment. **2020**, 12, 4959-4968	2
102	Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer. **2020**, 2020, 8860788	1
101	A four-gene signature associated with clinical features can better predict prognosis in prostate cancer. **2020**, 9, 8202-8215	4
100	Advanced Imaging of Biochemical Recurrent Prostate Cancer With PET, MRI, and Radiomics. **2020**, 10, 1359	2
99	DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy. **2020**, 80, 632-639	1
98	Systematic review and meta-analysis of trials evaluating the role of adjuvant radiation after radical prostatectomy for prostate cancer: Implications for early salvage. **2020**, 14, 330-336	3
97	Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?. **2020**, 214, 1248-1258	11
96	Exploratory cost-effectiveness analysis of Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer. **2020**, 37, 305-312	11
95	Effect of F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial. **2020**, 107, 316-324	26
94	The impact of extended pelvic lymph node dissection on the risk of hospital readmission within 180´days after robot assisted radical prostatectomy. **2020**, 38, 2799-2809	3
93	Candidates to salvage therapy after external-beam radiotherapy of prostate cancer: Predictors of local recurrence volume and metastasis-free survival. **2021**, 102, 93-100	1
92	Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer. **2021**, 81, 157-169	2

91	Management of Positive Surgical Margins After Radical Prostatectomy. **2021**, 1047-1058	
90	Malignant Evaluation and Clinical Prognostic Values of M6A RNA Methylation Regulators in Prostate Cancer. **2021**, 12, 3575-3586	4
89	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. **2021**, 15, E545-E552	0
88	Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy. **2021**, 11,	1
87	PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications. **2021**, 136, 109556	5
86	Restaging the Biochemical Recurrence of Prostate Cancer with [Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management. **2021**, 13,	2
85	White button mushroom (Agaricus bisporus) disrupts androgen receptor signaling in human prostate cancer cells and patient-derived xenograft. **2021**, 89, 108580	6
84	Tumor Biological Feature and Its Association with Positive Surgical Margins and Apical Margins after Radical Prostatectomy in Non-Metastasis Prostate Cancer. **2021**, 28, 1528-1536	1
83	Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries. **2021**, 7, 538-544	0
82	Parameters predicting [F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. **2021**, 11, 41	3
81	Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries. **2021**, 7, 545-549	2
80	Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer. **2021**, 11, 658331	2
79	Does Cancer Type Influence the Impact of Recurrence? A Review of the Experience of Patients With Breast or Prostate Cancer Recurrence. **2021**, 12, 635660	0
78	Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer. **2021**, 38, 80	1
77	Robotic Radical Prostatectomy at the Egyptian National Cancer Institute: Overcoming the Challenges in the Initial Case Series. **2020**, 9, 367-372	
76	Evaluation of Quantitative Ga-68 PSMA PET/CT Repeatability of Recurrent Prostate Cancer Lesions Using Both OSEM and Bayesian Penalized Likelihood Reconstruction Algorithms. **2021**, 11,	1
75	Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. **2021**, 11,	3
74	Proton vs. photon radiotherapy for MR-guided dose escalation of intraprostatic lesions. **2021**, 60, 1283-1290	1

73	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. **2021**,	4
72	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. **2021**, 98, 102206	11
71	A circular RNA, circSMARCA5, inhibits prostate cancer proliferative, migrative, and invasive capabilities via the miR-181b-5p/miR-17-3p-TIMP3 axis. **2021**, 13, 19908-19919	2
70	Prostate-Specific Membrane Antigen (PSMA) PET: A Counterpart to Prostate MRI. **2021**, 56, 376-383	
69	Imaging features of the evolving patterns of metastatic prostate cancer. **2021**,	1
68	Early Experience with Salvage Robotic-Assisted Radical Prostatectomy in Proton Beam Radiotherapy Failures. **2021**, 38, 310-315	
67	In vitro and in vivo comparative study of a novel Ga-labeled PSMA-targeted inhibitor and Ga-PSMA-11. **2021**, 11, 19122	1
66	A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence. **2021**, 225, 153587	2
65	Proteomic Landscape of Prostate Cancer: The View Provided by Quantitative Proteomics, Integrative Analyses, and Protein Interactomes. **2021**, 13,	2
64	Endogenous testosterone density predicts unfavorable disease at final pathology in intermediate risk prostate cancer. **2021**, 53, 2517-2526	0
63	Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer. **2021**, 16, e0258160	1
62	RSL3 enhances the antitumor effect of cisplatin on prostate cancer cells via causing glycolysis dysfunction. **2021**, 192, 114741	4
61	The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. **2019**, 201, 322-331	81
60	18F-Fluciclovine PET/CT in Therapeutic Decision Making for Prostate Cancer: A Large Single-Center Practice-Based Analysis. **2021**, 46, 187-194	4
59	Open approach, extended pelvic lymph node dissection, and seminal vesicle invasion are independent predictors of hospital readmission after prostate cancer surgery: a large retrospective study. **2020**, 72, 72-81	5
58	Assessment of biochemical recurrence of prostate cancer (Review). **2019**, 55, 1194-1212	8
57	Cancer stem cell and mesenchymal cell cooperative actions in metastasis progression and hormone resistance in prostate cancer: Potential role of androgen and gonadotropin-releasing hormone receptors (Review). **2020**, 56, 1075-1082	2
56	Molecular genetic aspects of prostate cancer radioresistance. **2021**, 20, 182-192	

55	Upregulation of Holliday junction recognition protein predicts poor prognosis and biochemical recurrence in patients with prostate cancer. **2019**, 18, 6697-6703		4
54	Collision metastasis: Renal cell carcinoma and prostatic adenocarcinoma to a retroperitoneal lymph node. **2022**, 40, 101884		1
53	Current and Future Management of Locally Advanced and Metastatic Prostate Cancer. **2020**, 22, 110-123		4
52	Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?. **2021**, 13, 17588359211051870		1
51	Comparison of Clinical Outcomes of Radical Prostatectomy versus IMRT with Long-Term Hormone Therapy for Relatively Young Patients with High- to Very High-Risk Localized Prostate Cancer. **2021**, 13,		1
50	A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology. **2021**, 16, e0259093		0
49	Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy. **2021**, 82, 245		2
48	Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study.. **2021**, 13,		0
47	Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?. **2021**, 13, 175883592110518		2
46	Effects of <italic>Lycium ruthenicum</italic> Murray anthocyanin Pt3G on the proliferation and apoptosis of prostate cancer LNCaP andPC-3 cells. **2021**,		
45	Current challenges in metastasis research and future innovation for clinical translation.. **2022**, 39, 263		0
44	A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer.. **2021**, 9, 774625		1
43	The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.. *Urologia Internationalis*, **2022**, 1-12	1.9	0
42	Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.. **2022**, 54, 541		0
41	Clinical and Biological Significance of DNA Methylation-Driven Differentially Expressed Genes in Biochemical Recurrence After Radical Prostatectomy.. **2022**, 13, 727307		1
40	Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.. **2022**, 22, 239		1
39	Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body ´Ga-PSMA-11 PET/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy?. **2022**, 12, 12		0
38	Moderate hypofractionation for salvage radiotherapy (HYPO-SRT) in patients with biochemical recurrence after prostatectomy: a cohort study with meta-analysis.. **2022**,		0

37	The Tobacco □Cembrenediol: A Prostate Cancer Recurrence Suppressor Lead and Prospective Scaffold via Modulation of Indoleamine 2,3-Dioxygenase and Tryptophan Dioxygenase.. **2022**, 14,		
36	Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact Survey 2018.. **2021**, 13, 9127-9137		0
35	Differences in Distribution and Detection Rate of the [Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11-Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer.. **2021**, 15,		0
34	Contrast-Enhanced Ultrasound-Magnetic Resonance Imaging Radiomics Based Model for Predicting the Biochemical Recurrence of Prostate Cancer: A Feasibility Study.. **2022**, 2022, 8090529		1
33	A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality.. **2022**, 14, 203-217		0
32	Precision intervention for prostate cancer: Re-evaluating who is at risk.. **2022**, 538, 215709		0
31	Management Impact of Metachronous Oligometastatic Disease Identified on 18F-Fluciclovine (Axumin®) PET/CT in Biochemically Recurrent Prostate Cancer.		0
30	Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study.		0
29	A gene prognostic index from cellular senescence predicting metastasis and radioresistance for prostate cancer. **2022**, 20,		0
28	A Prospective Study of MR-Guided Focal Salvage High Dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients. **2022**,		0
27	Prostate cancer: understanding patients□ treatment options.		
26	A radiation resistance related index for biochemical recurrence and tumor immune environment in prostate cancer patients. *Computers in Biology and Medicine*, **2022**, 146, 105711	7	0
25	Radiomics in prostate cancer: an up-to-date review. *Therapeutic Advances in Urology*, **2022**, 14, 17562872211090	3.2	9
24	Podemos usar a expressão de Ki67 para prever a agressividade do câncer de próstata?. *Revista Do Colegio Brasileiro De Cirurgioes*, 49,	0.5	
23	Can we use Ki67 expression to predict prostate cancer aggressiveness?. *Revista Do Colegio Brasileiro De Cirurgioes*, 49,	0.5	0
22	The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. *Nature Reviews Urology*,	5.5	0
21	Management of Extracapsular Extension and Positive Surgical Margins Following Robot-Assisted, Laparoscopic Radical Prostatectomy. **2022**, 373-384		0
20	EPM2A acts as a protective factor in prostate cancer, evidence from a real-world patient cohort. 13,		0

19	Single-fraction PSMA-PET - and multiparametric MRI -guided SBRT for Prostate Cancer Local Recurrences.	0
18	Emulation of a target trial with sustained treatment strategies: an application to prostate cancer using both inverse probability weighting and the g-formula.	0
17	PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. **2022**, 12, 2594	1
16	Identification and validation of a lipid metabolism gene signature for predicting biochemical recurrence of prostate cancer after radical prostatectomy. 12,	0
15	Minimal Residual Disease (MRD) and a New Immunotherapy in Locally Advanced Prostate Cancer. **2022**,	0
14	Exosome RNA Sequencing as a Tool in the Search for Cancer Biomarkers. **2022**, 8, 75	0
13	Focal nodular enhancement on DCE MRI of the prostatectomy bed: radiologic-pathologic correlations and prognostic value.	0
12	Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer. **2022**, 22,	0
11	Impact of Clinicopathological Characteristics and Tissue Inhibitor of Metalloproteinase-3 Polymorphism Rs9619311 on Biochemical Recurrence in Taiwanese Patients with Prostate Cancer. **2023**, 20, 306	0
10	Poorly Controlled Diabetes Mellitus Increases the Risk of Deaths and Castration-Resistance in Locally Advanced Prostate Cancer Patients. 1-9	0
9	Radiomics-Based Inter-Lesion Relation Network to Describe [18F]FMCH PET/CT Imaging Phenotypes in Prostate Cancer. **2023**, 15, 823	0
8	The natural history of a delayed detectable PSA after radical prostatectomy.	0
7	Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy. **2023**, 2023, 1-3	0
6	Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.	0
5	Robot-assisted radical prostatectomy following holmium laser enucleation of the prostate: Perioperative, functional, and oncological outcomes.	0
4	A Five Glutamine-Associated Signature Predicts Prognosis of Prostate Cancer and Links Glutamine Metabolism with Tumor Microenvironment. **2023**, 12, 2243	0
3	Retreatment Plan Success through Patient Health Awareness, Health Behavior, and Access to Doctor after a Focal Therapy Procedure for Prostate Cancer. **2023**, 47, 116-129	0
2	Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer. 14,	0

1	Post-diagnostic metformin and statin use and risk of biochemical recurrence in Veterans diagnosed with prostate cancer.	0